Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
Open Access
- 9 December 2016
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 18 (2), 241-250
- https://doi.org/10.1016/s1470-2045(16)30632-5
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinibBlood, 2016
- Rituximab intolerance in patients with Waldenström macroglobulinaemiaBritish Journal of Haematology, 2015
- Ibrutinib in Previously Treated Waldenström’s MacroglobulinemiaThe New England Journal of Medicine, 2015
- Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensusBlood, 2014
- A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemiaBlood, 2013
- XIII. Waldenström's macroglobulinaemia: an indolent B‐cell lymphoma with distinct molecular and clinical featuresHematological Oncology, 2013
- How to manage Waldenstrom’s macroglobulinemiaLeukemia, 2013
- MYD88 L265P Somatic Mutation in Waldenström's MacroglobulinemiaThe New England Journal of Medicine, 2012
- Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003